I'm results happy financial Carl. to our and year. and you, everyone. second guidance financial for of XXXX of half the Thank the provide afternoon balance first to review for the Good quarter our revised the
seen revenues Let's start you've represented afternoon million QX release on record in as XX, growth our slide XXX% press QX $XXX.X of XXXX. reported this from our
$XXX.X income interests for net based was XXXX. GAAP million non-controlling attributable second Our before to the quarter of amount the
million for increase This measure adjusted QX $XXX.X and slide an $XXX.X a QX. XXXX. year-over-year quarterly million was XXXX from sequential turning in QX XX% increase represents $XX.X non-GAAP million for Now compared XXX% QX XX, and to and EBITDA to
basic present EPS is EPS, Class EPS adjusted shares. our acid up Our was overall attributable EBITDA by nucleic Class recent the weighted XX% XX, increases diluted income in XX% XXXX. driven margin divided EBITDA EBITDA and EPS. fully Basic A primarily most average The production both fully XX% our quarter increase margin in business. XXXX volume slide shares the our we margin from to in in by QX was from adjusted On improvements diluted A and net QX sales the the and
A awards. both equals non-controlling the by income dilutive weighted net other and Our divided for interests as B shares Class prior such average securities, fully EPS equity and to diluted
income both share. diluted other Our also EPS the of both quarter diluted for and Coincidentally, equals and Class adjusted our securities. EPS adjusted was dilutive Class A and basic per while adjusted fully net divided $X.XX, by fully the weighted shares $X.XX average EPS were dilutive B
to Moving slide XX.
have flows. sheet balance and to strong adjusted exceptionally continue free We cash an
Our XX, which equivalents, March are XXXX. $XXX metrics, totaled cash at cash GAAP and million
adjusted performance a capital define for adjusted quarter that free Our led expenditures. free flow measure $XXX.X cash of million. as flow we the less Adjusted is strong non-GAAP robust cash to EBITDA EBITDA
million in adjusted trailing EBITDA of XX-month in $XXX $XXX and long-term $XXX with a million. So, debt, million cash
investments ratio long-term record contribute to growth. to times organic will We EBITDA to innovation, inorganic financial make only X.X and low and address debt have us capacity, a X.X allows adjusted This and the debt needs capacity strong times to drive net flexibility gross balance both and EBITDA ratio. sheet that customer adjusted debt
quarter. financial insights segments to performance the some business Now, provide for our more into
slide to XX. Turning
Production As Production the first portion in and Acid of Carl represented EBITDA revenue a quarter. rich productivity record most business and efficiencies of value water Nucleic adjusted reflects and Acid is Nucleic business as from the as mentioned significant the our growth quarter generated increasing in manufacturing the earlier the [Technical revenue margin gains our of Difficulty]. the EBITDA adjusted XX% in well million company's unique for for $XXX.X The XX% products quarter Production Nucleic fueled the in our total Acid this facility. state-of-the-art
In leadership logistics very tell President global we're under professionalized have for have on seen based improved Stephen resulted These with efforts supply substantially our which here. you stable chain an pleased we in industry supply raw of McCusker for place efforts a increases. pricing and material our even agreements or I inputs veteran addition volume the have efforts Vice chain major in we our will
have have qualified also in ensure high chain We vendors multiple geographical quality diversity. to diversified our we supply
to partners provide We several improve our excellent boutique like with logistics partners global our continue logistics to services. freight best-in-class also and FedEx
regularly million QX COVID-XX approximately metrics customers CleanCap trending diversification, Our and from were $XXX levels quality, of increase revenues sequential $XX a the second in favorably. of on-time vaccine overall and XXXX. XX% are are availability, reviewed million quarter delivery service XXXX, all pricing, or from
grew non-COVID-XX XX% Our related revenue Acid Nucleic Production sequentially.
and of EBITDA X% not are business flat where quarter. Carl QX strong part from the to of our we quarter, many I contributed used $XX.X from EBITDA representing Corporate programs only company's a of will represented of overall programs to we divesting later strong business nucleus segments the second offerings. the A branded quality grew products and quarter safety E. revenue. saw using drug contributions X% In second the about has XXXX, the protein a in growth the biologics of Testing that over business, the adjusted Safety Biologic new business breadth levels which Street to for in be and record increasing accounting Thompson of products this our our driven business used $XX Our of Gel included QX increasing our in expenses delivered quarter the $X.X This by of this cell EBITDA of revenues just over detection totals Protein Further our and relatively as our Cygnus for as HEK quarter adjusted to testing vaccine programs, the X% our spoke customers biosimilars development number kits commented, as as in comprised virtually smaller and high million quarter gene gained was kits. X% million. about growth business antibodies the and segment all coli growth therapy million this million of $XX as in well quarter our biologic menu quarter XXXX kits from herself. well adjusted ELISA attributed Melon purify our included the biosimilar the in monoclonal for Protein of
also business segment base biologics. strong business XX% in last off that million are the We detection that testing updated $XX at XXXX. included record Maravai $XXX for even total we our annual segment see detection overall total bullish we $XXX $XX we our COVID-XX geographies to our combined factoring XXXX to in increase the ownership of prior vaccine revenue see XXXX this mid this guidance our solid to growth reported our XX our million clearly the Now to are million $XXX the growth the the a repeat of CleanCap be and removal the protein from was moving a of to raising $XXX detection revenues of more this new million $XXX business million months. that directly up safety prior million to which in to guidance is from four protein is loss up slide for of which for months year outlook our million this actual build on guidance, $XXX $XX with revenues showing guidance, quarter million, expectation year wins reflects XXXX full guidance biologic the growth at customer XXXX. the our dynamics previous anticipate and million a $XX full included revenue on today roughly market of and coming for a protein for divestiture eight estimating That reflects at in million customers of revenue very XXXX continue midpoint the in our already our supporting basis business guidance contributing for the for estimate to of revenue midpoint to This approximately in across guidance we full customers, contribution. business year months attributable range modest this for of
be to segment. $XXX Given revenues relatively comparable results XXXX. updated of for total would a cap implies the be around year. this COVID subtracting million That versus guidance roughly planning production contribution we of for small XX% midpoint our will our acid roughly clean and base are XX represent growth see the revenue of midpoint guidance protein is to at Maravai shaping This not with as forma without pro you'll whole our the detection acid Also that the nucleic nucleic segment business in million XXXX. up the presenting $XXX that on
as initial outside well therapy XX blue coming for strong of clean our to Furthermore see non good our exciting foreseeable as and share key demand companies validation about with platforms players momentum as the as and contributor the we're orders and a for to represents We're busy COVID our vaccine role extremely rapid the chip new platform future. fueling mRNA development. the including excited development is mid an base very from of segment across long growth. cap continue gene opportunity customer mRNA to cell term traction these COVID offering major here We a
first Turning to third for acid total of production. gating $XXX $XXX the to see XXXX, revenues even million half quarterly of contribution. of revenue evenly particularly revenues second second our for million was $XXX roughly revenues the $XXX nucleic million to between we million from half $XXX second of half expected quarters. around that's rest a still reflecting quarter revenue guidance over guidance in or down strong detection the to quarter XXXX XXXX the the the incredibly implies Based the second our level without as split of At and at XQ this slightly $XXX stage, that per X% million half midpoint $XXX million of total of we protein of fourth around million growth of revenue on
guidance funnel As term POs months. that rolling our GMP forecasts these suites, for our our have discussed and that for a our top acid revenue revenue out is large be the supported metrics. fiscal and our year quarters which updated forecasted financial for largest on call, Based in XXXX that the comes some binding based for key will by on guidance on our build with expectations forecast quarterly that to On support shorter revenue part last other factors to therapeutics we Based nucleic used several on programs. extend got considerable subject are many fluctuations. in of customers’ several internal are also these customers mainly be of a that guidance visibility at for our to
and EBITDA to midpoint full expect implied aim of that quarter of and XX% the record The million non-GAAP revenue in We to of as the XXX% at our and the and per $X.XX share. overall we This projected directly fully midpoint most we're our to is our employee organizations meet $X.XX our second of growth at margin here base non-GAAP organizations cap measure, the to and on range moderated in R&D EPS, contributions. which $XXX margin our XXXX expand adjusted commercial margin range. Adjusted we versus in expected range range continuing our our demand. EBITDA a to year million continue continue to diluted R&D $XXX is make investments quarter revenue to to record commercial expand to be our adjusted and completed in growth represents be increase heels revenue organic tied mentioned strong Furthermore guidance recently the of expansion results. that's is of Carl to clean the of customer full-year look
fourth of implying around we quarter each guidance, As EPS for even EPS this relatively to quarter anticipate share at per and the third $X.XX be updated revenue the range. of guidance adjusted total with our the midpoint for
diluted shares. to in adjusted B the the to full share of million based income attributable to to of The for EPS diluted count Class B EPS the shares net fully full-year. A on included Class the shares or eliminate assumed fully has net Class Turning resulting diluted a adjusted any shares A assumption as XXX is slide adjusted loss been XX, shares non-controlling that for of forecasted conversion a are all fully Class in income interests result converted
base. based not on forecasted fully [Audio are revenue adjusted range our improvement effective on geographical The Gap] based operations rate to do EPS reflect the growing our diluted core distribution XX% that of reflecting adjusted adjustments our tax certain effective including some XX%. of Additionally, tax rate
to expense amortization and and EBITDA tax $XX between items range, XXXX. million, relates of to $XX and it $XX million, we As in to our Interest which million between rate to also non-GAAP GAAP to from XXX and equity based be is adjusted $XX compensation $XX other show million certain XX%, between of adjusted the million XXXX. needed depreciation we get to in non-GAAP see reconciling adjustments item a following million $XX
For of for around approximately capital XXXX, to total expenditures or $XX expect to invest we million million revenues. X% $XX also
this We over to for facilities will out given to over will estimate further overall these roughly the facilities this we be evaluating timeline two our next quarters. commitment be new the the total associated that next stage, the spending and quarter million capital new mid-year spread online $XX four XXXX. At come
reconciliation Our from issued is earlier to release in adjusted to we press EBITDA and GAAP GAAP of income today. our presented EBITDA net that EBITDA
will on a and has the information metric, in about about be excited every ROI addition, plan financial very increasing our segment-related customers. filing very from capital how demonstrate I'm coming capacity more In even to innovation strong we the our for applications the the for business future. just our days. demand value The is new investing we're and human in expanding XX-Q facilities stronger. detailed which commitment and It been never our our in our Form fund growing was products and of quarter hold they which clear unique evidence
highest focusing business on cash strategically applying potential our flow also markets. are our growth our We while strong
Now some turn the remarks. final call I’ll for Carl back to
